Glucose decreases the ability of HNF4α to activate the transcription of the <i>NR2F2</i> proximal promoter and to bind its chromatin target. by Marie Boutant (164748)

Overexpression of SOCS1 decreases the antiviral effect of IFN-γ and tyrosine phosphorylation of STAT1 during MHV-68 infection in NIH3T3 fibroblasts. by Yong Shen (284972)

Co-localization of LysoTracker and Mtb-phagosomes is decreased by <i>H</i>. <i>diminuta</i> and <i>T</i>. <i>muris</i> antigen treatment. by Naomi Aira (3743911)

The synchronous activity of SGN fiber populations is disrupted and their response to sound is decreased with increasing levels of <i>L</i>_<i>u</i> heterogeneity. by Maral Budak (6680351)

Calcium release from <i>S</i>. <i>mutans</i> at decreasing pHs. by Tarcísio Jorge Leitão (4811379)

Comparison between mean-field solutions and simulations on networks. by Valeria d’Andrea (12095838)

Decreased proliferation in <i>Csf1r^−/−</i> and <i>Csf1^op/op</i> mouse colonic epithelium. by Duy Huynh (381445)

“…Bar = 50 µm. Means are depicted by horizontal bars, n = 3 per group, *<b>*</b>P<0.01, *P<0.05, using unpaired two-tailed t-test. …”

IQG-607 decreases the infection of macrophages by <i>L</i>. <i>braziliensis</i> amastigotes. by Camila F. Amorim (676792)

BrdU-positive mossy cell precursors are decreased in the hilus of developing Rac1^N/Rac3^KO mice. by Roberta Pennucci (83950)

Decreased pMHC avidity and CD8β-independence for functional avidity of D^bNPN3A-primed T cells for D^bNP₃₆₆. by Sophie A. Valkenburg (176257)

Immunohistochemical detection of myeloperoxidase, CD3 and CD45 in the pancreas during experimental AP. by Sebastian Weis (161447)

Immunohistochemical detection and quantification of myeloperoxidase, CD3 and CD45 positive cells in the lung during experimental AP. by Sebastian Weis (161447)

Map of the study area, representing the 50 provinces, divided between the 6 different regions. by Jacopo Cerri (6271958)

Ranking of genotypes according to the ideotype for each trait and the percentage difference (increase or decrease) in relation to cv. M-82. by Herika Paula Pessoa (13254326)

<i>In-vitro</i> drug release profiles of (a) amlodipine, (b) hydrochlorothiazide, and (c) candesartan. by Anjuman Arora (750291)

Subjects:

FT-IR spectra of (a) amlodipine (b) hydrochlorohiazide and (c) candesartan nanoparticles. by Anjuman Arora (750291)

Subjects:

Characterization of the optimized nanoparticles (These values are means of a minimum of 5 batches). by Anjuman Arora (750291)

Subjects:

PK profiles of the developed nanoparticles vs. free drugs in rats (a) amlodipine, (b) hydrochlorothiazide, and (c) candesartan. by Anjuman Arora (750291)

Subjects:

TEM images of (a) amlodipine (b) hydrochlorothiazide and (c) candesartan nanoparticles. by Anjuman Arora (750291)

Subjects:

PK profile of: (a) The developed NanoFDC and (b) Combination of the free candidate drugs. by Anjuman Arora (750291)

Subjects: